Anzeige
Meldung des Tages: Golden Cross bestätigt ein Fosterville-ähnliches System — und jetzt wird tiefer gebohrt

Alkermes News

Aktie
WKN:  A1JKVH ISIN:  IE00B56GVS15 US-Symbol:  ALKS
29,55 €
-0,45 €
-1,50%
07:27:06 Uhr
Depot/Watchlist
Marktkapitalisierung *
3,94 Mrd. €
Streubesitz
100,00%
KGV
-
Index-Zuordnung
-

Alkermes News

11.09.25 - PR Newswire
Alkermes Announces Launch of 8th Annual Alkermes Pathways Research Awards® Program
Alkermes Announces Launch of 8th Annual Alkermes Pathways Research Awards® Program PR Newswire
08.09.25 - PR Newswire
Alkermes Presents Detailed Positive Results from Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at World Sleep Congress 2025
Alkermes Presents Detailed Positive Results from Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at World Sleep Congress 2025 PR Newswire
08.09.25 - PR Newswire
Alkermes Presents Detailed Positive Results from Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at World Sleep Congress 2025
Alkermes Presents Detailed Positive Results from Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at World Sleep Congress 2025 PR Newswire
25.08.25 - PR Newswire
Alkermes to Present Detailed Positive Results From Vibrance-1 Phase 2 Study Evaluating Alixorexton in Patients With Narcolepsy Type 1 at World Sleep 2025
Alkermes to Present Detailed Positive Results From Vibrance-1 Phase 2 Study Evaluating Alixorexton in Patients With Narcolepsy Type 1 at World Sleep 2025 PR Newswire
25.08.25 - PR Newswire
Alkermes to Present Detailed Positive Results From Vibrance-1 Phase 2 Study Evaluating Alixorexton in Patients With Narcolepsy Type 1 at World Sleep 2025
Alkermes to Present Detailed Positive Results From Vibrance-1 Phase 2 Study Evaluating Alixorexton in Patients With Narcolepsy Type 1 at World Sleep 2025 PR Newswire
29.07.25 - PR Newswire
Alkermes plc Reports Second Quarter 2025 Financial Results
Alkermes plc Reports Second Quarter 2025 Financial Results PR Newswire
29.07.25 - PR Newswire
Alkermes plc Reports Second Quarter 2025 Financial Results
Alkermes plc Reports Second Quarter 2025 Financial Results PR Newswire
21.07.25 - PR Newswire
Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1
Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-​Daily Alixorexton in Patients With Narcolepsy Type 1 PR Newswire
21.07.25 - PR Newswire
Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1
Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-​Daily Alixorexton in Patients With Narcolepsy Type 1 PR Newswire
15.07.25 - PR Newswire
Alkermes to Report Second Quarter Financial Results on July 29, 2025
Alkermes to Report Second Quarter Financial Results on July 29, 2025 PR Newswire
15.07.25 - PR Newswire
Alkermes to Report Second Quarter Financial Results on July 29, 2025
Alkermes to Report Second Quarter Financial Results on July 29, 2025 PR Newswire
02.06.25 - PR Newswire
Alkermes to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
Alkermes to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference PR Newswire
02.06.25 - PR Newswire
Alkermes to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
Alkermes to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference PR Newswire
02.06.25 - PR Newswire
Alkermes Highlights Data From Psychiatry Portfolio at Spring 2025 Scientific Conferences
Alkermes Highlights Data From Psychiatry Portfolio at Spring 2025 Scientific Conferences PR Newswire
02.06.25 - PR Newswire
Alkermes Highlights Data From Psychiatry Portfolio at Spring 2025 Scientific Conferences
Alkermes Highlights Data From Psychiatry Portfolio at Spring 2025 Scientific Conferences PR Newswire
29.05.25 - PR Newswire
Alkermes to Present New Research Related to ALKS 2680 at SLEEP 2025
Alkermes to Present New Research Related to ALKS 2680 at SLEEP 2025 PR Newswire
29.05.25 - PR Newswire
Alkermes to Present New Research Related to ALKS 2680 at SLEEP 2025
Alkermes to Present New Research Related to ALKS 2680 at SLEEP 2025 PR Newswire
01.05.25 - PR Newswire
Alkermes plc Reports First Quarter 2025 Financial Results
Alkermes plc Reports First Quarter 2025 Financial Results PR Newswire
01.05.25 - PR Newswire
Alkermes plc Reports First Quarter 2025 Financial Results
Alkermes plc Reports First Quarter 2025 Financial Results PR Newswire
30.04.25 - PR Newswire
New Survey Provides Insights into Diagnosis and Treatment Journey for People Living With Alcohol Use Disorder (AUD)
New Survey Provides Insights into Diagnosis and Treatment Journey for People Living With Alcohol Use Disorder (AUD) PR Newswire

Newssuche

Videos

newspaper
09:20 Uhr 0,00%
Technical Trading: DAX Long kurzfristig
DAX Long Typ: Turbo Open End WKN: VJ9H40 Hebel:11,30 Laufzeit: OpenEnd Einstieg: Market ... Mehr »